Physician profile
Michelle Eisenfeld
NPI 1205158169
$7,108.11
in general payments reported to CMS, 2019-2025
23 companies · $627 in 2025
The $627 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,050 · 2021: $1,029 · 2022: $1,495 · 2023: $732 · 2024: $863 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186 · Education: $35.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.27 |
| Education | $35.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,145.49 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,494.82 | 2019-2024 | Trelegy Ellipta, Nucala, Shingrix |
| Genzyme Corporation | $620.70 | 2019-2024 | |
| Csl Behring | $470.30 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Pfizer INC. | $418.35 | 2019-2024 | |
| Optinose US, INC. | $386.26 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $363.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $303.85 | 2020-2024 | Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $255.42 | 2019-2024 | Dupixent |
| Kaleo, INC. | $187.35 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $101.29 | 2020-2025 | Xolair |
| Amgen INC. | $53.21 | 2023-2024 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $48.78 | 2025 | Neffy |
| Organon LLC | $44.11 | 2025 | Nexplanon, Vtama |
| Aimmune Therapeutics, INC. | $43.87 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $33.67 | 2024 | Vtama |
| Abbvie INC. | $24.69 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.76 | 2019 | |
| Phadia US INC. | $19.93 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.86 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $15.46 | 2025 | Ayvakit |
| Alk-Abello, INC | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Eisenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.